Clinical Trial Update: An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the optimal dose of tofacitinib to achieve low disease activity or clinical remission in active rheumatoid arthritis from clinical an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Norman B. Gaylis, MD | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED